Omega Healthcare (OHI) director reports $40-per-share sales totaling 2,500 shares

Rhea-AI Filing Summary

Insider sale by a director: The Form 4 shows that director Lisa Egbuonu-Davis reported two open-market sales of Omega Healthcare Investors (OHI) common stock on 08/08/2025: 200 shares at $40.16 and 2,300 shares at $40.157318,654 shares beneficially owned.

Insights

Corporate Governance Expert

TL;DR: Director disclosed routine sales totaling 2,500 OHI shares at roughly $40 each, reducing reported beneficial ownership to 18,654 shares.

The reported transactions are straightforward open-market dispositions by a company director. The Form 4 lists two sales on the same transaction date at very similar prices, suggesting execution around the same trading window. There is no accompanying information about any Rule 10b5-1 plan or other pre-arranged plan in the filing text provided. From a governance perspective, such filings are standard disclosures required for transparency but do not on their face indicate governance concerns.

Securities Analyst

TL;DR: Insider sold 200 and 2,300 OHI shares at about $40.16; the trades disclose nothing about company fundamentals or material corporate events.

For investors, these transactions signal insider liquidity rather than new information about the business. The prices reported ($40.16 and $40.1573) provide specific execution levels; the filing does not disclose intent or use of proceeds. Absent further context—such as size relative to total insider holdings or linkage to a trading plan—these sales are neutral from a market-impact standpoint.

08/11/2025 - 04:10 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Egbuonu-Davis Lisa

(Last) (First) (Middle)

303 INTERNATIONAL CIRCLE

SUITE 200

(Street)

HUNT VALLEY MD 21030

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
OMEGA HEALTHCARE INVESTORS INC [ OHI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/08/2025		S		200	D	$40.16	20,954	D
Common Stock	08/08/2025		S		2,300	D	$40.1573	18,654	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Meghan C. Lyons, Attorney-in-Fact	08/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did OHI report in this Form 4?

Director Lisa Egbuonu-Davis reported two sales on 08/08/2025: 200 shares at $40.16 and 2,300 shares at $40.1573

How many OHI shares does the reporting person own after the transactions?

The filing shows the reporting person beneficially owned 18,654 shares following the reported transactions.

Were the reported transactions purchases or sales for OHI insider activity?

Both reported transactions are sales (transaction code S) of common stock.

Do the Form 4 disclosures mention a trading plan (Rule 10b5-1)?

The text provided does not include any statement that these sales were made pursuant to a Rule 10b5-1 plan.

Who signed the Form 4 filing for the reporting person?

The filing was signed by an attorney-in-fact, Meghan C. Lyons, on behalf of the reporting person.